OphtiMed Rx
Novel Molecular Treatment for Dry Age-related Macular Degeneration
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in November 2021 by Dana Rabinovich, OphtiMed Rx operates with 1–10 employees. The company has secured $1.3M in total capital across one funding round from one investor, G.O Innovation, to advance its novel molecular therapy for dry age-related macular degeneration.
Business overview
OphtiMed Rx is a Health Tech &. The company's core technology, OM-301, is designed to protect retinal cells from senescence and halt the progression of dry AMD, aiming to prevent vision loss and improve patient independence.
Log in to access full profile ›Company Intelligence Q&A
- What is OphtiMed Rx's primary focus?
- OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease that causes blindness. Their treatment, OM-301, aims to protect retinal cells from cellular aging and stop the progression of dry AMD.
- When was OphtiMed Rx founded?
- OphtiMed Rx was founded in November 2021.
- Who is a co-founder of OphtiMed Rx?
- Dana Rabinovich is a co-founder and CEO of OphtiMed Rx.
- What is the total capital raised by OphtiMed Rx?
- OphtiMed Rx has raised $1.3M in total capital.